After first saying no, the U.K.'s National Institute for Health and Care Excellence (NICE) published draft guidance recommending Perjeta (pertuzumab, Roche Holding AG) for treating people who have had surgery for early HER2-positive breast cancer and whose cancer has already spread to their lymph nodes.